PA
AXDX

Perceptive Advisors’s Accelerate Diagnostics AXDX Stock Holding History

Perceptive Advisors’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-75
Closed -$16K – 171
2015
Q4 		$16K Buy
+75
New +$13.7K ﹤0.01% 150

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Perceptive Advisors's AXDX Position: Q1 2016 in Review

Perceptive Advisors sold out of Accelerate Diagnostics (AXDX) in Q1 2016, closing a stake of 75 shares — an estimated $16K sold.

Perceptive Advisors first reported a position in AXDX in Q4 2015 and held it in 1 quarter. The position peaked at $16K in Q4 2015. 92 funds tracked by Wall St. Rank hold AXDX as of Q1 2016.

  • Perceptive Advisors reported no remaining Accelerate Diagnostics position as of Q1 2016 after selling out during the quarter.
  • Perceptive Advisors sold 75 Accelerate Diagnostics shares in Q1 2016, an estimated $16K.
  • Perceptive Advisors first reported a position in Accelerate Diagnostics in Q4 2015 and held it in 1 quarter.
  • Perceptive Advisors's Accelerate Diagnostics position peaked at $16K in Q4 2015.
  • 92 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2016.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.